Dermatophagoides Pteronyssinus / House Dust Mite
House dust mite extract (Dermatophagoides pteronyssinus and D. farinae) is an allergy extract used by trained physicians to diagnose mite allergy with skin tests and to treat it with allergy injections.
🧬 Where this information comes from
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
House dust mite extract is used by allergy specialists in skin tests to confirm mite allergy and then as allergy shots to treat it, usually after avoiding mites and allergy medicines fall short; it has been on the market since about 1986. Most people tolerate the shots well, with redness, itching, swelling or tenderness at the injection spot that can last a few days. The boxed warning is about severe, sometimes life-threatening allergic reactions, so you stay in the office at least 20 minutes after every shot. Tell your specialist about asthma (steroid-dependent asthma carries the highest risk), heart problems and every medicine you take, beta blockers above all.
Clinical pearls
- Mention fever, infection, flaring asthma or heavy dust exposure before a shot, since the dose may need delaying or lowering.
- Report swelling at the shot site that lasts longer than 24 hours, because any reaction usually means the next dose is reduced.
- Expect a lower dose when you start a new vial or switch from a different extract, even if you were at maintenance.
- Belly cramps, nausea, vomiting or diarrhea after a shot can signal a whole-body reaction, so tell the office right away.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
This extract can cause severe, sometimes life-threatening allergic reactions. It should be given only by physicians experienced with allergy extracts, or under an allergy specialist's guidance.
People with asthma, especially those dependent on steroids, are at higher risk. You should be watched for at least 20 minutes after treatment, and emergency care must be available. Know the warning signs of a reaction and contact your doctor's office if they occur.
The starting dose is based on skin testing. If you are switching from another type of extract, you start as if new to treatment. Switching to a new lot also means a lower dose. Beta blockers may make epinephrine less effective. The product must never be injected into a vein.
Patient Information Guide A plain-language walkthrough of Dermatophagoides Pteronyssinus / House Dust Mite, written from its FDA label.
What Dermatophagoides Pteronyssinus / House Dust Mite Is Used For
▾
Standardized mite extract is used for both diagnosis and treatment of mite allergy.
- Diagnosis of people with a history of allergy to mites or house dust (skin testing).
- Treatment of people with a history of mite allergy and sensitivity confirmed by skin testing (subcutaneous injections).
How Dermatophagoides Pteronyssinus / House Dust Mite Works
▾
In skin testing, the extract causes allergen to bind IgE antibodies on mast cells. These cells release histamine and other substances, producing a visible reaction. How the injections work as treatment is not well understood. It is generally believed that this therapy (hyposensitization) helps reduce house dust allergy symptoms.
Dermatophagoides Pteronyssinus / House Dust Mite Dosage
▾
This extract is given only by healthcare professionals. Skin tests use a scratch, prick-puncture or intradermal method. Treatment is given as injections under the skin, starting with a very diluted amount. Dosing is highly individualized.
- Injections are usually given once or twice a week until a maintenance dose is reached.
- Intervals may then stretch to every 2, 3 and eventually 4 weeks.
- If you miss your visit by a long time, the dose is lowered.
- An average course of treatment is about three to five years.
Dosing details from the FDA-approved label
From the Dermatophagoides Pteronyssinus / House Dust Mite prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Diagnostic use: Percutaneous (scratch or prick-puncture) tests
- The skin test concentration of 10,000 AU/mL in dropper vials is used for scratch or prick-puncture testing
- Skin tests are graded in terms of the wheal and erythema response noted at 15 to 20 minutes
- Diagnostic use: Intradermal tests
- Only after a scratch or prick-puncture test has been administered with a negative result, test intradermally with 0.02 to 0.05 mL of a 10 AU/mL (1:1,000 v/v of the 10,000 AU/mL concentrate)
- If this test is negative, a second intradermal test may be performed using a 100 AU/mL (1:100 v/v dilution of 10,000 AU/mL concentrate)
- Extract for intradermal testing is prepared by diluting the 10,000 AU/mL stock concentrate in bulk vials with sterile saline with or without human serum albumin.
- Therapeutic use: Subcutaneous injection, patients who appear highly sensitive by history and skin test (initial dose)
- Initial dose 0.05 mL of a 0.1 AU/mL dilution or as established by skin test titration
- The amount is increased at each injection by not more than 50% - 100% of the previous amount, and the next increment is governed by the response to the last injection
- Maximum: The upper limits of dosage have not been established; however, doses larger than 0.2 mL of the concentrate may be painful due to the glycerin content of the extract.
- Dosage is highly individualized. Large local reactions persisting longer than 24 hours: repeat or reduce the previous dose. Any systemic reaction: reduce the subsequent dose by at least 50%.
- Therapeutic use: Injection interval and maintenance
- Injections are given one or two times per week until the maintenance dose is reached
- Then the injection interval may be increased to 2 weeks, then to 3 weeks and finally to 4 weeks
- If the patient does not return for 6 to 8 weeks after the last injection, reduce the dose to 25% of the last dose. If longer than 8 weeks, a dose reduction of one, two or three dilutions may be made.
- Therapeutic use: Switching to fresh extract
- The initial dose should be reduced to one-quarter (25%) of the previous dose
- Therapeutic use: Duration of treatment
- The usual duration of treatment has not been established
- A period of three to five years of injection therapy constitutes an average course of treatment
- Children and older age patients
- Appear to tolerate injections of allergenic extract well, and no special recommendations need to be made for these groups
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The product should be discarded if discoloration or particles are observed. DIAGNOSTIC USE: Percutaneous Tests : The skin test concentration of 10,000 AU/mL in dropper vials is used for scratch or prick-puncture testing. Puncture tests performed with D. farinae extract on 5 persons sensitive to mite showed a mean diameter wheal of 8.8 mm ± 1.8 mm and mean diameter erythema of 39.2 mm ± 5.3 mm. Puncture tests with D. pteronyssinus extract on 10 persons sensitive to mite showed a mean diameter wheal of 7.8 mm ± 4.1 mm and mean erythema of 33.7 mm ± 12.0 mm. Intradermal Tests : Extract for intradermal testing should be prepared by diluting the 10,000 AU/mL stock concentrate in bulk vials with sterile saline with or without human serum albumin. Intradermal skin tests (0.05 mL) in persons highly sensitive to mite showed the following results: Table 1 AU/mL to elicit 50 mm sum of diameter erythema reaction Allergen No. of Persons Mean Range D. farinae 5 0.0040 0.0013-0.0124 D. pteronyssinus 10 0.0031 0.0001-0.1416 Intradermal tests should only be performed after a scratch or prick-puncture test has been administered with a negative result. Patients who do not react to a valid scratch or prick-puncture test should be tested intradermally with 0.02 to 0.05 mL of a 10 AU/mL (1:1,000 v/v of the 10,000 AU/mL concentrate). If this test is negative, a second intradermal test may be performed using a 100 AU/mL (1:100 v/v dilution of 10,000 AU/mL concentrate). Skin tests are graded in terms of the wheal and erythema response noted at 15 to 20 minutes. Wheal and erythema size may be recorded by actual measurement of the extent of both responses. THERAPEUTIC USE: The dosage of mite extract administered by subcutaneous injection is highly individualized and varies according to the degree of sensitivity of the patient, his clinical response and tolerance to the extract administered during the early phases of an injection regimen. In patients who appear to be highly sensitive by history and skin test, the initial dose of the extract should be 0.05 mL of a 0.1 AU/mL dilution or as established by skin test titration.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Dermatophagoides Pteronyssinus / House Dust Mite Side Effects
▾
The most common reactions happen at the injection site.
Common side effects
- Redness at the injection site
- Itching at the injection site
- Swelling at the injection site
- Tenderness or pain at the injection site
- Local reactions that can last several days
When to get medical help
- Call for emergency help right away if you have trouble breathing, wheezing, throat tightness or swelling of the face or throat.
- Get help for widespread hives, itching, flushing, dizziness, faintness or loss of consciousness.
- Tell the office right away about nausea, vomiting, belly cramps or diarrhea after an injection.
- Report large local reactions that last longer than 24 hours.
- Stay in the office for at least 20 minutes after each injection so reactions can be treated quickly.
These can start within minutes to hours and last several days. Cold packs and oral antihistamines may help. Severe whole-body reactions can include hives, swelling, wheezing, low blood pressure, shock and loss of consciousness. Deaths have occurred rarely.
Dermatophagoides Pteronyssinus / House Dust Mite Warnings and Precautions
▾
- Severe allergic reactions can be life-threatening, especially in people with steroid-dependent asthma.
- Stay for at least 20 minutes after each injection.
- Doses may be held or lowered with severe asthma or rhinitis symptoms, infection or flu with fever, or heavy allergen exposure.
- A new vial or different extract type requires a lower dose.
- Never inject into a vein.
Dermatophagoides Pteronyssinus / House Dust Mite Interactions
▾
One interaction matters most.
- Beta-blocking drugs: they can make epinephrine less effective if it is needed to treat a severe allergic reaction.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before Taking Dermatophagoides Pteronyssinus / House Dust Mite
▾
- Previous anaphylaxis to mites, skin testing or allergy shots.
- Bleeding disorders.
- Autoimmune disease.
- Recent heart attack.
- Children with nephrotic syndrome.
- Asthma, especially steroid-dependent asthma.
- Immunotherapy should start only after mite allergy is confirmed by skin testing.
Dermatophagoides Pteronyssinus / House Dust Mite Overdose
▾
A strong local reaction can be treated with oral antihistamines and a cold compress. No more extract should be given until the reaction has completely cleared, and the dose must be lowered. A whole-body reaction needs immediate treatment with epinephrine.
What Dermatophagoides Pteronyssinus / House Dust Mite Does in the Body
▾
In skin testing, the extract triggers histamine release and other substances when allergen meets IgE antibodies on mast cells. This produces a wheal (raised bump) and erythema (redness) that are measured at about 15 to 20 minutes. Treatment is generally believed to reduce symptoms of house dust allergy, though how it works is not well understood.
How to Store Dermatophagoides Pteronyssinus / House Dust Mite
▾
Extract should be stored at 2-8°C since higher temperatures may adversely affect stability. Do not freeze.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Dermatophagoides Pteronyssinus / House Dust Mite: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Dermatophagoides Pteronyssinus / House Dust Mite — the kind of thing our pharmacy team would talk through with you at the counter.
What is this extract used for?
▾
Why do I have to wait in the office after my shot?
▾
What side effects are normal?
▾
When should I get urgent help?
▾
Does it matter if I take a beta blocker?
▾
What if I miss shots or feel sick on shot day?
▾
Is Dermatophagoides Pteronyssinus / House Dust Mite available over the counter?
▾
When was Dermatophagoides Pteronyssinus / House Dust Mite first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More About Dermatophagoides Pteronyssinus / House Dust Mite on HelloPharmacist
Dermatophagoides Pteronyssinus / House Dust Mite Forms and Strengths (How It Comes)
Dermatophagoides Pteronyssinus / House Dust Mite is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Dermatophagoides Pteronyssinus / House Dust Mite inactive ingredients by manufacturer.
Injection
How this form is used
- House Dust Mite (D. farinae and D. pteronyssinus) extract is used to diagnose mite or house dust allergy through skin testing.
- House Dust Mite (D. farinae and D. pteronyssinus) extract is used to treat people with mite allergy confirmed by skin testing.
- House Dust Mite extract is used for scratch, prick-puncture or intradermal skin tests, with results read at about 15 to 20 minutes.
- House Dust Mite extract for treatment is given as subcutaneous injections, with the dose individualized by the physician.
- House Dust Mite extract must be diluted before first use for treatment or intradermal testing, and must never be injected into a vein.
- House Dust Mite extract should be checked for particles or discoloration, and discarded if either is seen.
Dermatophagoides Pteronyssinus / House Dust Mite on the U.S. Market: Products, Makers and Brands
How Dermatophagoides Pteronyssinus / House Dust Mite appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Dermatophagoides Pteronyssinus / House Dust Mite product record with the FDA, mostly as injection; the earliest marketing or approval year on record is 1986.
Compare Dermatophagoides Pteronyssinus / House Dust Mite Products
A representative set of FDA-listed product records for Dermatophagoides Pteronyssinus / House Dust Mite — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 10000 [AU]/mL | Cutaneous, Intradermal, Subcutaneous | Allermed Laboratories, Inc. | BLA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Dermatophagoides Pteronyssinus / House Dust Mite NDCs →
Dermatophagoides Pteronyssinus / House Dust Mite Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Dermatophagoides Pteronyssinus / House Dust Mite — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Dermatophagoides Pteronyssinus / House Dust Mite in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Dermatophagoides Pteronyssinus / House Dust Mite FDA Approval History
How Dermatophagoides Pteronyssinus / House Dust Mite went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Dermatophagoides Pteronyssinus / House Dust Mite Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Dermatophagoides Pteronyssinus / House Dust Mite recalls since July 2021.
✅No Dermatophagoides Pteronyssinus / House Dust Mite recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Oct 8, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one exact multiple-ingredient concept (MIN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). A product with a different ingredient combination belongs on a different page.
RxCUI 1116982 2 dose forms · 3 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 1116981In current FDA listingsClinical drug / strength (SCD) American house dust mite allergenic extract 15000 AU/ML / European house dust mite allergenic extract 15000 AU/MLRxCUI 1192764American house dust mite allergenic extract 5000 AU/ML / European house dust mite allergenic extract 5000 AU/MLRxCUI 1192787 -
Dose form (SCDF) Sublingual Tablet RxCUI 1998623No current FDA listingClinical drug / strength (SCD) American house dust mite allergenic extract 6 SQ-HDM / European house dust mite allergenic extract 6 SQ-HDMRxCUI 1998624
Look up RxCUI 1116982 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Dermatophagoides Pteronyssinus / House Dust Mite Supply and Shortage Status
Whether Dermatophagoides Pteronyssinus / House Dust Mite is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Who Makes Dermatophagoides Pteronyssinus / House Dust Mite: Manufacturers and Labelers
One company lists Dermatophagoides Pteronyssinus / House Dust Mite products with the FDA. By number of product records, the largest are Allermed Laboratories, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Dermatophagoides Pteronyssinus / House Dust Mite Drug Class (RxNorm)
Dermatophagoides Pteronyssinus / House Dust Mite belongs to the Standardized Insect Allergenic Extract class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for This Dermatophagoides Pteronyssinus / House Dust Mite Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Allermed Laboratories, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →